Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial

Authors: Jeffrey M. Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B. Nixon, Michael Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F. Patz

Source: Nature Communications, Vol 16, Iss 1, Pp 1-10 (2025)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/d6c5fe0d4de14eb8a7276b6c8c2bf723

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis

Authors: Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

Source: Journal for ImmunoTherapy of Cancer, Vol 13, Iss 2 (2025)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/13/2/e010395.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/60e5a4ef436f4acf917577af2440e287

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

Authors: Quincy Chu, MD, Natasha B. Leighl, MD, Veerle Surmont, MD, Carla van Herpen, MD, PhD, Anne Sibille, MD, Ben Markman, MD, Stephen Clarke, MD, Rosalyn A. Juergens, MD, PhD, Mirelis Acosta Rivera, MD, Vladimir Andelkovic, MD, Charles M. Rudin, MD, PhD, Stephanie Snow, MD, Dong-Wan Kim, MD, Michael Sanatani, MD, Hongxia Lin, PhD, Kinjal Sanghavi, PhD, Sarah Tannenbaum-Dvir, MD, Paul Basciano, MD, Deanne Lathers, PhD, Katarzyna Urbanska, PhD, Georgia Kollia, PhD, Chunsheng He, PhD, Andrew DiPiero, BS, Yu Liu, MD, PhD, Neal Ready, MD, PhD

Source: JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100400- (2022)

Subject Terms: BMS-986012, Nivolumab, Combination therapy, SCLC, Fucosyl-GM1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322001242; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/f5bd2944b1a6435ab4a355125a671725

636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study

Authors: Scott Antonia, Jeffrey Clarke, Thomas Stinchcombe, John Hartman, Jeffrey Crawford, Monica Bodd, Susan Locke, Kris Herring, Neal Ready, Jesse Troy, Chakita Williams, Steven Wolf, Thomas LeBlanc

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/6e7012c1baf340f48033297e799e7164

909 Differentiation subgroups within LKB1-deficient lung cancer influence both the immune exclusion phenotype and cellular composition of the immune microenvironment

Authors: David Carbone, Neal Ready, Jacob Kaufman, Doug Cress, Theresa Boyle, Kris Wood

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/8162ccd8e2ca42f5a04d7e9eba8e689d

Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB‐IV nonsmall cell lung cancerInformed consent was obtained from the subjects and/or guardians.

Authors: Wallace Akerley, Howard Safran, Ken Zaner, Neal Ready, Tony Mega, Teresa Kennedy

Source: Cancer (0008543X); Sep2006, Vol. 107 Issue 5, p1050-1054, 5p

A Low Rate of Central Nervous System Progression in a Phase II Trial of Outpatient Chemobiologic Therapy With Cisplatin, Temozolomide, Interleukin-2, and Interferon Alfa 2-B for Metastatic Malignant Melanoma.

Authors: Neal Ready

Source: American Journal of Clinical Oncology; Oct2005, Vol. 28 Issue 5, p479-484, 6p